Rocket Pharmaceuticals (RCKT) has closed the $180 million sale of its rare pediatric disease priority review voucher, the company said Friday.
The voucher was granted by the US Food and Drug Administration in March 2026 in connection with the approval of Kresladi, Rocket's gene therapy for severe leukocyte adhesion deficiency-I, a rare and life-threatening primary immunodeficiency disease, the company said.
The sale increases Rocket's cash, cash equivalents and investments to around $322.6 million, which is expected to fund operations into Q2 2028, the company said.
Shares of the company were up 5.3% in Friday premarket trading.